目的 探討防風通圣顆粒聯(lián)合奧司他韋治療普通型病毒性肺炎的臨床療效。方法 選取2020年3月—2021年4月中國中醫(yī)科學院廣安門醫(yī)院收治的92例普通型病毒性肺炎患者，按隨機數(shù)字表法將所有患者分為對照組和治療組，每組各46例。對照組口服磷酸奧司他韋膠囊，75mg/次，2次/d。治療組在對照組基礎上溫水沖服防風通圣顆粒，3g/次，2次/d，當腋下體溫＞37.3℃時用藥劑量調整為6g/次，2次/d。兩組療程7d。觀察兩組療效，比較治療前后兩組典型癥狀評分、臨床肺部感染評分（CPIS）、肺炎胸片吸收評價量表評分以及血清程序性細胞死亡因子5（PDCD5）、C反應蛋白（CRP）、高遷移率族蛋白B1（HMGB1）、白細胞介素（IL）-1β水平。結果 治療后，治療組總有效率是95.65%，顯著高于對照組的82.61%（P<0.05）。治療后，兩組患者發(fā)熱評分、日間咳嗽評分、夜間咳嗽評分、咯痰評分、胸悶痛評分均較治療前顯著降低（P<0.05），治療后，治療組典型癥狀評分低于對照組（P<0.05）。治療后，兩組CPIS評分、肺炎胸片吸收評價量表評分均較治療前顯著降低（P<0.05）；治療后，治療組CPIS評分、肺炎胸片吸收評價量表評分顯著低于對照組（P<0.05）。治療后，兩組血清PDCD5、CRP、HMGB1、IL-1β水平均顯著低于治療前（P<0.05）；且治療后，治療組血清PDCD5、CRP、HMGB1、IL-1β水平均顯著低于對照組（P<0.05）。結論 防風通圣顆粒聯(lián)合奧司他韋治療普通型病毒性肺炎有確切療效，能明顯改善患者肺炎典型癥狀，減輕肺部感染程度，并能有效抑制機體細胞凋亡以及炎癥反應，利于病情緩解，且安全性較好，具有一定的臨床推廣應用價值。

Objective To investigate the clinical efficacy of Fangfeng Tongsheng Granules combined with oseltamivir in treatment of common viral pneumonia. Methods A total of 92 patients with common viral pneumonia admitted to Guang’anmen Hospital of China Academy of Chinese Medical Sciences from March 2020 to April 2021 were selected. All patients were divided into control group and treatment group according to the random number table method, with 46 cases in each group. Patients in the control group were po administered with Oseltamivir Phosphate Capsules, 75 mg/time, twice daily. Patients in the treatment group were po administered with Fangfeng Tongsheng Granules with warm water on the basis of the control group, 3 g/time, twice daily, and the dose was adjusted to 6 g/time, twice daily when the armpit temperature was higher than 37.3 ℃. The treatment course of the two groups was 7 d. The efficacy of the two groups was observed. The typical symptom score, clinical pulmonary infection score (CPIS), pneumonia chest radiograph absorption assessment scale score, and serum programmed cell death factor 5 (PDCD5), C-reactive protein (CRP), high mobility group B1 (HMGB1), interleukin-1β levels were compared between the two groups before and after treatment. Results After treatment, the total effective rate of the treatment group was 95.65%, which was significantly higher than 82.61% of the control group (P < 0.05). After treatment, the scores of fever, daytime cough, night cough, sputum cough and chest pain in the two groups were significantly lower than those before treatment (P < 0.05). After treatment, the scores of typical symptoms in the treatment group were lower than those in the control group (P< 0.05). After treatment, the CPIS score and the Pneumonia chest Radiograph absorption assessment scale score of the two groups were significantly lower than those before treatment (P < 0.05). After treatment, the CPIS score and the pneumonia chest radiograph absorption assessment scale score of the treatment group were significantly lower than those of the control group (P< 0.05). After treatment, the levels of serum PDCD5, CRP, HMGB1 and IL-1β in the two groups were significantly lower than those before treatment (P< 0.05). After treatment, the serum levels of PDCD5, CRP, HMGB1 and IL-1β in the treatment group were significantly lower than those in the control group (P< 0.05). Conclusion Fangfeng Tongsheng Granules combined with oseltamivir has definite curative effect in the treatment of common viral pneumonia, and can significantly improve the typical symptoms of pneumonia, reduce the degree of lung infection, and effectively inhibit apoptosis and inflammatory reaction of the body, can be conducive to the remission of the disease with good safety, which has certain clinical application value.

R974